一日双响！君联资本同日收获两家IPO

Group 1: Investment Strategy and Market Positioning - Junlian Capital successfully invested in leading companies in the AGI and surgical robotics sectors, with a long-term investment strategy that includes nine rounds of funding for Zhipu and three for Jingfeng Medical [1][3][5] - The AGI market in China is projected to exceed 1 trillion yuan by 2030, with a compound annual growth rate (CAGR) of over 63% [4] - Junlian Capital has established a comprehensive investment landscape in the AI sector, focusing on three main areas: vertical applications of AI, foundational large models, and AI infrastructure [4] Group 2: Company Highlights - Zhipu, founded in 2019, has developed the GLM series of large models, achieving significant milestones such as surpassing 100 billion parameters and ranking first in domestic evaluations [3][4] - Jingfeng Medical, established in 2017, is a leading surgical robotics company in China, recognized for its innovative technology and multiple regulatory approvals for various surgical robots [6][7] - Both companies' listings mark a significant achievement for the Social Security Fund's Zhongguancun Special Fund, highlighting Junlian Capital's investment acumen in hard technology [7]